Page 105 - 202010

波生坦治疗新生儿缺氧性肺动脉高压的临床观察 Δ

2 #
陈 波 ，白 波 ，李广洪 ，黄学良 ，罗惠玲 ，黄惠仪（1.南方医科大学附属花都医院医院感染管理科，广州
1＊
2
2
2
2
510800；2.南方医科大学附属花都医院新生儿科，广州 510800）
中图分类号 R969；R722.1 文献标志码 A 文章编号 1001-0408（2020）10-1247-06
DOI 10.6039/j.issn.1001-0408.2020.10.17
摘 要 目的：观察波生坦治疗新生儿缺氧性肺动脉高压（HPH）的有效性和安全性。方法：选择2014年1月－2019年3月于我院
新生儿科住院治疗的82例HPH新生儿为研究对象，按是否加用波生坦治疗分为波生坦组（50例）和非波生坦组（32例）；另选取25
例血清标本留取时间、出生胎龄、日龄等一般资料与波生坦组匹配的非HPH新生儿为对照组。所有HPH新生儿均给予持续静脉
滴注盐酸多巴胺注射液5 mg/（kg·min），直到肺动脉收缩压（PASP）正常；在此基础上，波生坦组患儿加用波生坦片1 mg/kg（用适
量注射用水溶解后喂服），q12 h，连用72 h。分析HPH患儿血清内皮素1（ET-1）水平与PASP的关系，并比较治疗前后波生坦组和
非波生坦组HPH患儿的PASP和疗效以及3组患儿的动脉血气指标变化及不良反应发生情况。结果：治疗前，波生坦组患儿血清
ET-1水平为（164.3±115.3）pg/mL，显著高于对照组的（41.9±3.7）pg/mL，且与PASP呈正相关（r＝0.864，P＜0.001）。波生坦组患
儿的治疗总有效率为 90.00％，显著高于非波生坦组的 71.88％（P＜0.05）。治疗 72 h 后，两组患儿的 PASP 均较治疗前显著下降
（P＜0.001），且波生坦组显著低于非波生坦组（P＜0.05）；3组患儿的动脉血氧分压、动脉血氧饱和度、动脉血二氧化碳分压和氧合
指数均较治疗前显著改善（P＜0.05），且波生坦组的动脉血氧分压、动脉血氧饱和度和氧合指数均显著高于非波生坦组（P＜
0.05）。在波生坦治疗期间及停药1周内，均未发现有患儿血清乳酸脱氢酶、天冬氨酸转氨酶、丙氨酸转氨酶及血清肌酐水平有明
显变化。3组患儿喂养不耐受、贫血、白细胞及血小板减少的发生率比较，差异均无统计学意义（P＞0.05）。结论：波生坦可改善
HPH患儿的氧合状态，降低PASP，且短期用药是安全的。
关键词 缺氧性肺动脉高压；内皮素1；波生坦；新生儿；疗效；安全性

Clinical Observation of Bosentan in the Treatment of Hypoxic Pulmonary Hypertension in Neonates
1
2
2
2
2
2
CHEN Bo ，BAI Bo ，LI Guanghong ，HUANG Xueliang ，LUO Huiling ，HUANG Huiyi（1. Dept. of Nosocomial
Infection Management，Huadu Hospital Affiliated to Southern Medical University，Guangzhou 510800，China；
2. Dept. of Neonatology，Huadu Hospital Affiliated to Southern Medical University，Guangzhou 510800，China）
ABSTRACT OBJECTIVE： To observe the effectiveness and safety of bosentan in the treatment of hypoxic pulmonary
hypertension （HPH） in neonates. METHODS：From Jan. 2014 to Mar. 2019，a total of 82 HPH neonates hospitalized in the
department of neonatology of our hospital were selected as research subjects. According to whether or not receiving bosentan
therapy，50 cases were included into bosentan group and 32 cases into non-bosentan group. Meanwhile，another 25 non-HPH
neonates with serum sample retention time and general information such as gestational age at birth and day age matching the HPH
group were selected as the control group. All neonates with HPH were given continuous intravenous infusion of Dopamine
hydrochloride injection 5 mg/（kg·min）until PASP was normal. On this basis, neonates in the bosentan group were additionally
given Bosentan tablets 1 mg/kg （fed after dissolving with appropriate amount of water for injection） for q12 h，72 h. The
relationship between serum ET-1 levels of neonates with HPH and PASP was analyzed，as well as PASP before and after treatment
and therapeutic efficacy between bosentan and non-bosentan groups，the changes of arterial blood gas indexes and ADR in 3 groups
were compared. RESULTS：Before treatment，the serum ET-1 levels of bosentan group was（164.3±115.3）pg/mL，which was
significantly higher than（41.9±3.7）pg/mL of control group and positively correlated with PASP level（r＝0.864，P＜0.001）. Total
response rate of bosentan group was 90.00％，which was significantly higher than 71.88％ of non-bosentan group（P＜0.05）. After
72 h of treatment，PASP of 2 groups was decreased significantly，compared with before treatment（P＜0.001），and the bosentan
group was significantly lower than the non-bosentan group（P＜0.05）. The PaO2，SaO2，PaCO2 and OI in 3 groups was significantly
improved compared with that before treatment（P＜0.001），and the PaO2，SaO2 and OI in the bosentan group was significantly
higher than that in the non-bosentan group（P＜0.05）. During the treatment period of bosentan and within one week after drug
withdrawal，there was no significant change in serum LDH，AST，ALT and Scr levels in neonates. There was no statistically
significant difference in the incidence of feeding intolerance，anemia，reduced WBC and reduced PLT in 3 groups（P＞0.05）.
CONCLUSIONS： Bosentan can improve the oxygenation
Δ 基金项目：广东省科技计划项目（No.2017ZC0442）；广州市花
status of neonates with HPH, reduce PASP，and short-term
都区科技计划项目（No.HD14WS001）
medication is safe.
＊副主任医师。研究方向：新生儿感染。E-mail：hdrybjk@126.
KEYWORDS Hypoxic pulmonary hypertension； ET-1；
com
# 通信作者：主任医师，硕士。研究方向：新生儿呼吸系统疾病。 Bosentan；Neonate；Efficacy；Safety
E-mail：gzhdbaib2004@163.com

中国药房 2020年第31卷第10期 China Pharmacy 2020 Vol. 31 No. 10 ·1247 ·